Evidence map›Paper›PMID 37519535›Full record

ArticleCureus2023

COVID-19 and Kidney Disease (KD): A Retrospective Investigation in a Rural Southwestern Missouri Region Patient Population.

Kailey J Kowalski, Shilpa Bhat, Mariah Fedje, Greg Stahl, Nova Beyersdorfer, Darrin S Goade, Kerry Johnson, Robert Arnce, Robert Hillard

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kailey J KowalskiCollege of Medicine, Kansas City University, Joplin, USA.
Shilpa BhatCollege of Medicine, Kansas City University, Joplin, USA.
Mariah FedjeCollege of Medicine, Kansas City University, Joplin, USA.
Greg StahlQuality Improvement, Freeman Health System, Joplin, USA.
Nova BeyersdorferPrimary Care, Kansas City University, Joplin, USA.
Darrin S GoadePharmacy, Freeman Health System, Joplin, USA.
Kerry JohnsonMathematics, Missouri Southern State University, Joplin, USA.
Robert ArncePrimary Care, Kansas City University, Joplin, USA.
Robert HillardPathology and Anatomical Sciences, Kansas City University, Joplin, USA.
Missouri Southern State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies have linked pre-existing kidney disease (KD) to higher rates of mortality due to coronavirus disease 2019 (COVID-19) infection. In the rural Midwest, where KD is prevalent, the impact of COVID-19 has been significant in a population that includes many patients on Medicare or Medicaid.

methodsA retrospective cohort study was performed assessing patients with acute kidney injury (AKI), chronic kidney disease (CKD) and end stage renal disease (ESRD), with and without COVID-19. International Classification of Diseases 10

resultsThe 95% confidence interval (CI) of the mortality rate of patients with COVID-19 and any degree of KD, encompassing both AKI and CKD, was between 30.21% and 37.63%. This metric was significantly higher than the 95% CI of COVID-19 infection (6.70%-9.96%, p<0.0001) or KD alone (10.89%-13.01%, p<0.0001). Within those with COVID-19 and KD, the highest rate of mortality was in patients with AKI (38.13% and 49.02%). There was not sufficient statistical support in our sample to assert that COVID-19 increased mortality in ESRD patients.

conclusionsBased on our results, patients with KD and COVID-19 are at higher risk for mortality when compared to patients with KD alone. Further studies are warranted into individual comorbidities affecting KD patient outcomes with COVID-19.

Indexed as

acute kidney injury (aki)chronic kidney failure (ckd)coronavirus disease 2019 (covid-19)end stage renal disease (esrd)kidney disease (kd)midwest

Identifiers

PMID37519535
PMCPMC10374171
OpenAlexW4382468918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.